CMV burden in immunosupressed patients

  • Research type

    Research Study

  • Full title

    A retrospective study on the burden of cytomegalovirus disease in immunosuppressed patients following transplantation in England

  • IRAS ID

    216924

  • Contact name

    Riccardo Cipelli

  • Contact email

    Riccardo.Cipelli@harveywalsh.co.uk

  • Sponsor organisation

    Astellas

  • Duration of Study in the UK

    0 years, 7 months, 30 days

  • Research summary

    A retrospective matched cohort study will be performed to understand the clinical and economic significance of CMV disease. The study will be conducted using data from the Hospital Episodes Statistics (HES), a database recording all hospitalizations in England and from the Office for National Statistics (ONS) mortality data.
    The HES records of all patients who underwent a solid organ or an allogeneic stem cell transplantation who were admitted to an NHS hospital in England will be selected for the source cohort, and assessed for cytomegalovirus (CMV) disease exposure according to the ICD-10 codes in the HES record.
    Each transplant recipient diagnosed with CMV disease will be matched to patients without CMV disease (controls) according to ICD-10 codes. The selected HES records will be linked with ONS records and the mortality at 12 months, in the CMV-exposed and non-exposed cohorts compared to assess the impact of CMV on mortality. The resource use of the two cohorts, as recorded in HES will also be compared to assess the economic impact of CMV exposure.

  • REC name

    Wales REC 7

  • REC reference

    17/WA/0010

  • Date of REC Opinion

    9 Jan 2017

  • REC opinion

    Favourable Opinion